All Assays articles – Page 6
-
NewsQTX153 reverses Rett symptoms and crosses key drug delivery barrier
QTX153, a novel HDAC6 inhibitor, has shown significant symptom reversal in preclinical models of Rett syndrome. This represents progress toward a therapy for a condition with no approved options.
-
NewsSmall molecule therapy improves islet transplant success in diabetes
A study from Weill Cornell Medicine shows that pre-treating pancreatic islet cells with a small molecule cocktail significantly improves survival after transplantation in type 1 diabetes models. The approach could help make donor cells go further and transplants more efficient.
-
ArticleTime for change: non-human primates in drug research
As ethical pressures and new regulations shake up preclinical research, the industry faces a turning point: can we finally move beyond non-human primates? Dr Mariana Argenziano, Associate Director Manufacturing Technologies at Ncardia, discusses the innovations reshaping drug development and what’s coming next.
-
ArticleFuture-proofing drug development with GenAI
Using GenAI and expert reasoning, drug developers can now explore an asset’s long-term potential as early as the preclinical stage. This shift is helping to reshape pipeline planning and refine therapeutic strategy.
-
News
How bowel cancer beats treatment - and how AI can stop it
Scientists have developed a new AI-guided tool that predicts how bowel cancer becomes resistant to treatment – which could lead to development of new personalised therapies.
-
ArticleSolving the disconnect between lab and data scientists: part 2
As the lab–data science divide continues, Ian Kerman looks ahead to a future of deeper collaboration – one where shared skills, smarter tools and a shift in mindset could finally break down the barriers. In this second interview, he shares his vision, practical ideas and advice for the next generation ...
-
NewsExperimental drug targets gene driving severe seizures in children
Researchers at the Fralin Biomedical Research Institute are developing a targeted KCNT1 inhibitor that has shown early promise in reducing seizures in preclinical models.
-
NewsScientists grow 3D brain that mimics the real thing
Researchers at POSTECH have developed a new 3D brain model that closely mimics the structure and function of human brain tissue – marking a major advance in early disease detection.
-
News3D model reveals hidden drivers of smell regeneration
Scientists have developed a simple- 3D mouse tissue model to study how the nose regenerates smell-sensing neurons. The goal is to create an organoid system that can be used to screen potential therapies for smell loss.
-
ArticleThe next phase of the multiomics evolution, powered by AI
Genomics laid the foundation for precision medicine, but on its own, it offers only part of the picture. This article explores how integrated multiomics can provide the deeper biological context needed to drive more effective therapies forwards.
-
ArticleA spatial approach to understanding drug dynamics using mass spectrometry imaging
What if you could actually see where a drug travels in the body down to the cellular level. Find out how mass spectrometry imaging (MSI) is making that possible – reshaping drug development from the inside out.
-
NewsSB000: a safer path to anti-aging therapies
Shift Bioscience has announced new aging research, highlighting the discovery of SB000. This novel single-gene target reverses cellular aging without activating dangerous pluripotency pathways.
-
NewsEngineered DNA aptamers outsmart viral infection pathways
EPFL scientists have engineered virus-inspired DNA aptamers that bind infection targets with record selectivity. This innovation could change how we diagnose and treat infectious diseases.
-
NewsInside the immune ‘handbook’ set to disrupt fibrosis research
Nearly a billion people are affected by chronic organ scarring, yet treatments remain limited. Now, Duke-NUS researchers have compiled a scientific ‘handbook’ of immune cell insights that could fast-track breakthroughs in fibrosis therapy.
-
ArticleShifting the ADC focus from antibody to payload
While ADCs continue to attract attention in oncology, many developers remain focused on antibodies – overlooking the critical role of payload design. At Sygnature Discovery, Dr Joshua Greally is leading a shift in perspective, advocating for a payload-first approach through the company’s new platform, NewPath ADC. In this interview, he ...
-
WebinarOptimizing antibody leads in early drug discovery with key developability insights
Stop costly biologic failures. This masterclass reveals high-throughput strategies to optimize antibody leads upfront.
-
NewsScientists create advanced 3D liver model mimicking real tissue
Scientists have developed a 3D liver model, known as the periportal assembloid. This model replicates the liver’s complex structure and bile transport system, enabling more precise study of disease progression.
-
NewsExperimental peptide targets glioblastoma’s most resilient cells
An experimental peptide from Virginia Tech may offer a new way to stop glioblastoma from coming back by disrupting the cancer’s treatment-resistant core.
-
NewsChemical hack turns platelets into drug couriers
Researchers at the University of Illinois have achieved the first successful metabolic labelling of platelets, a key step toward using them in targeted drug delivery. The technique could enable short-lived, precision therapies for cancer, immune conditions, and clotting disorders. ...
-
NewsTargeting PLA2G15 to treat neurometabolic disorders
Scenic Biotech and Stanford University have published a study identifying PLA2G15 as a new drug target in neurodegenerative and metabolic diseases, potentially enabling future treatments for conditions like Niemann-Pick type C.